Shenzhen New Industries Biomedical Engineering Co., Ltd. (SNIBE) develops, manufactures and sells clinical laboratory instruments and in vitro diagnostic reagents for hospitals and testing institutions worldwide. The company offers chemiluminescence immunoassay analyzers including the MAGLUMI X8, X6, X3, X10 and M series; biochemistry and electrolyte analyzers such as Biossays C10, C8, 240 Plus and E6 Plus; integrated systems like Biolumi CX8; lab automation solutions including the open fully automatic sample processing system SATLARS T8 and SATLARS-TCA; molecular diagnostic analyzers such as Molecision R8, S6, MP-32 and MP-96 with associated test menus; hemostasis analyzers like Hemolumi H6; and point-of-care testing products, supported by extensive chemiluminescence, biochemistry and molecular diagnostic reagent portfolios covering up to 260 CLIA parameters for applications in gonads, thyroid, glucose metabolism, kidney function, infectious diseases and more. SNIBE operates through segments encompassing instruments and supporting software, reagents, and accessories; it serves markets in Asia, Europe, America, Africa and beyond from its headquarters at No.23 Jinxiu East Road, Pingshan District, Shenzhen, China, where it was founded in 1995 and employs approximately 2,841 staff across a 55,000 square meter modern production facility. Recent developments include the acquisition of land use rights in Shenzhen's Pingshan District for 80 million yuan covering 37,831.7 square meters to construct the No. 5 Snibe building as a new headquarters facility; participation in major 2025 trade shows such as MEDICA, ADLM and Euromedlab to showcase diagnostic solutions; the SATLARS T8 winning the iF DESIGN AWARD 2025; approval of 2024 dividends payable in May 2025; and sustained R&D investment exceeding 15% of revenue to drive molecular diagnostics and international expansion particularly in Southeast Asia.